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Introduction
The  central  nervous  system  (CNS)  consists  of  two
major cell types, neurones and  glial  cells. Neuronal
communication with other neurones or glial cells is
effected mainly through neuro-transmitters and pep-
tides,  while  glial  cells  appear  to  use  an  abundant
range of factors for the communication  with either
neurones  or  other  glial  cells.  The  communication
between  neurones  can  span  large  distances  in  the
body, while glial cell communication is mainly local or
paracrine. During the past decade it has become clear
that the glial cells named after glue (= glia) have more
functions besides acting as a “nerve-glue” to form the
brain.
1,2 The glial  cells  appeared to  be essential  for
neuronal  protection, survival  and  outgrowth during
development and for the neuronal degeneration and
regeneration  under  pathological  conditions.  In  this
review we summarize glial cell functions and focus on
the  role,  production  and  regulation  of  nitric  oxide
(NO),  a  molecule  which  has  been  shown  to  be
involved in various neuroimmune processes.
Glial Cells
Glial  cells  can  be  divided  into  microglial  cells  and
macroglial cells, the latter of which are subdivided in
astroglial  cells  and  oligodendrocytes. The  oligoden-
drocytes are known for their myelin production that
wraps the axons in the white matter of the brain, and
are affected in diseases like multiple sclerosis (MS).
Glial  cell  activation  has  been  indicated  in  many
neuropathological  diseases  like  Alzheimer’s  dis-
ease,
3–7 Parkinson’s  disease,
5 multiple  sclerosis,
8
acquired  immune  deficiency  syndrome  (AIDS)
dementia complex (ADC)
9–11 and other disorders.
Microglial cells
Microglial cells, formerly named Hortegaglia or Meso-
glia, have been described in detail for the first time in
1932 by Del Rio-Hortega
12 considered as the father of
microglia. Microglial cells are ubiquitously distributed
in  the  CNS,  show  heterogeneous  morphology  and
comprise up to 20% of the total glial cell population in
the brain.
13 It was Del Rio-Hortega who proposed that
microglial cells occur in two morphologically distinct
forms, the ameboid  or macrophage-like form repre-
senting as active microglial cells seen in developing
brain and at sites of injury. These cells convert into the
highly branched ramified microglial cells
14 –17 viewed
as quiescent cells in the mature CNS
18 which even-
tually can transform into active macrophages (reactive
microglial  cells)  (Fig.  1).
19,20 Del  Rio-Hortega  sug-
gested that microglial cells served as macrophages or
phagocytic  cells,  which  has  found  substantial
support.
21–23
The  name  mesoglia  was  derived  from  their  pro-
posed  mesodermal  origin.  Indeed  more  recent  and
elaborative studies support a bone-marrow origin
17,24
from the usual macrophage precursor. Blood mono-
cytes or monocyte precursors invade the brain during
development.
25,26 In  studies  using  chimeric  rats,
support  was  found  for  the  bone  marrow  origin
hypothesis
27,28 but in other rat chimera experiments
the contrary was found.
29,30 The prevailing concept is
however that blood monocytes are the precursors of
ameboid microglial cells. There is apparently no need
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Mediators of Inflammation, 7, 239–255 (1998)for the influx of a large number of monocytes into the
brain  parenchyma  under  normal  conditions,  since
microglial cells have an extreme long life and have a
low  turnover  rate.
31,32 Their  numbers  can  be  aug-
mented by local proliferation
19,33–36 or by immigra-
tion of blood monocytes.
37 Under pathological condi-
tions  increased monocyte  infiltration  into  the  brain
parenchyma is found
8,38,39 and the influx is suggested
to be mediated by the microglial cell derived chem-
okine MCP-1
40 or adhesion molecules.
Microglial cell functions
The microglial cells serve as immunoregulatory cells,
and  are  essential  for  resistance  to  inter-  and  intra-
cellular pathogens. The microglial cells are present in
a  resting  or  a  ramified  form  (Fig.  2)  and  are  very
important in immunosurveillance. After activation of
the resting cells the microglial cells exhibit a highly
potent phagocytic activity  of foreign organisms and
material, phagocytosis of injured or necrotic tissue,
antimicrobial  immunity,  elimination  of tumour  cells
and  regulate  inflammatory  responses.
41 Microglial
cells have been reported to possess Fc receptors,
18,42
CD4 antigen
43 and major histocompatibility complex
(MHC)  class  I  and  II  antigens
41,44 –46 and  thus  are
antigen  presentating  cells.  Interferon-g and  inter-
leukin-4  (IL-4)  up-regulate  MHC  class  II  expression
and induce microglial cell proliferation.
47 In addition,
microglial cells show chemotaxic activity, like mono-
cytes  and  macrophages,  to  several  immunological
factors  such  as  complement  factor  C5a  and  to
transforming growth factor b (TGFb ) suggesting that
these cells can move to sites of injury  and thereby
participate  in  an  inflammatory  response.
12,42,48,49
These observations have led to a redefinition of the
brain as immune privileged site a concept based on
lack of inflammatory responses through the absence
of T and B cells.
Microglial  cells  share  many  functional  character-
istics with cells of the monocytic lineage. Interleukin-1
(IL)-1 production by microglial cells has been demon-
strated for the first time by Giulian,
50 and later by many
others
41,51–54 and IL-1 is found to be present in injured
brain tissue.
50,55 Other cytokines produced by micro-
glial cells are  TNF-a ,
54,56,57 IL-6
57–59 and TGFb
60–62 and
they produce prostanoids such as prostaglandin  E2,
(PGE2),  PGD2,  thromboxane
63,64 and  leukotrienes,
LTB4,  LTC4 and  5-HETE.
65 IL-5  was  found  to  be
produced by microglial cells in vitro which may be
involved  in  the  interaction  between  glial  cells  and
immune  cells  in  the  brain.
66 IL-10  and TGFb both
immunosuppressive and anti-inflammatory cytokines,
have been demonstrated to be produced by human
microglial  cells  and  down-regulate  microglial  cell
functions.
60,67–71These properties confirm that micro-
glial  cells  can  initiate  and  regulate  immune  and
inflammatory responses within the brain.
Astroglial cells
Astrocytes,  oligodendrocytes  and  neurons  are  of
ectodermal  origin,  and  derive  from the  neuroepite-
lium  of  the  primitive  neural  tube.  Astroglial  cells,
unlike neurones, retain the ability to divide through-
out life.
72 The multipotential stem cell develops into
the  bipotential  progenitor  cell  and  finally  the  glial
lineage-restricted  progenitor  cell  which  can  differ-
entiate into the oligodendrocyte, the astrocyte type 1
and type 2.
73 –76 The astrocytes outnumber neurones
10:1 in  mammalian  brain,  and as their  name imply,
they have a star-shaped morphology. The astrocytes
can  be identified by using specific markers such as
glial  fibrillary  acidic  protein  (GFAP),  and  glutamine
synthase  (GS),  that  are  specific  for  both  types  of
astroglial cells.
77–81
Each cell forms processes that  contact the blood
vessels,  where  they  form  the  so-called  end-feet  or
sucker processes which also forms part of the blood–
brain  barrier  (BBB)  together  with  endothelial  cells
and  the  lamina  basalis.
72 Astrocytes  in  the  white
matter  are  referred  to  as  fibrous  astrocytes,  with
numerous fibrils within their cytoplasm. In the grey
matter, the astrocytes generally contain few fibrils and
are  called  protoplasmic  astrocytes.  Interestingly,  in
vitro also two types of astrocytes can be identified,
type 1 and type 2 astrocytes which are thought to be
in  vitro analogous  of  the  protoplasmic  and  fibrous
astrocytes respectively
82 (Fig. 2).
Astroglial cell functions
Initially  the  function  of astroglial  cells was  thought
to  be  a  structural  support  within  the  CNS,  with
their  processes  having  junctions  with  other  astro-
glial  cells,  endothelial  cells  and  neurones.  In  addi-
V. A. M. Vincent et al.
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FIG. 1. Microglial cell activation cascade. Schematic drawing
illustrating the transition of microglial cells from ramified
microglial cells to the ameboid microglial cell, adapted from
Ref. 371.tion  in  repair  mechanisms  the  astroglial  cells  fill
open spaces by proliferating and thereby forming a
glial  scar.
83–86
It  is  now  known  that  astroglial  cells  are  very
important  cells  in  the  outgrowth  and  survival  of
neurones during development and in neuropathology.
Astroglial cells produce nerve growth factor (NGF)
87
in vitro and  in vivo and  the production  of NGF is
increased by IL-1,
88–92 TNFa ,
93 IL-4 and IL-5.
94 Other
neurotrophic factors produced by astroglial cells are
ciliary  neurotrophic  factor  (CNTF),  brain-derived
neurotrophic  factors  (BDNF)  and  fibroblast  growth
factor (FGF).
95,96
Astrocytes produce cytokines like IL-1,
41,97–100 IL-
6,
101 IL-3,
102 TGFb
60,62,103–105 and IL-15
106 and factors
like prostaglandin E2 (PGE2),
97,99,107,108 granulocyte-
macrophage  colony-stimulating  factor  (GM-
CSF)
109,110 and microglial mitogens (MM).
111 TNFa is
also  produced  by  astroglial  cells  in  vitro after
lipopolysaccharide  (components  of  Gram-negative
bacterial  outer  membranes;  LPS)
56,112 and  IL-1b
stimulation
59,106 or mycoplasma infection.
108
Astrocytes can be induced to express MHC I and II
class  molecules  in  vitro and  are  able  to  present
antigen
113,114 and thus are important immune cells in
the brain. However, in contrast to microglial cells they
do  not  express  significant  levels  of  MHC  class  II
molecules
115 in vivo.
Glia–glia interactions
Recent  studies  have  shown  various  interactions
between  microglial  cells  and  astroglial  cells.  IL-1
produced  by  microglial  cells  has  been  shown  to
stimulate  astroglial  cell  proliferation  in vitro.
116–119
Intracerebral injections of IL-1 or local production of
IL-1 by microglial cells elicit astrogliosis which may
result  in  scar  formation
120,121 and  thereby  have  a
negative effect on axonal outgrowth and remyelina-
tion.  In  addition  the  microglial  cells  influence  the
production  of  NGF  by  astroglial  cells,  which  is
enhanced  after  IL-1  and  IL-5  both  produced  by
microglial cells.
66,94,122
On the other hand, astroglial cells influence micro-
glial cell functions. Interleukin-3 (IL-3) is mitogenic to
microglial  cells  and  has  been  suggested  to  be  pro-
duced by astrocytes.
102,123 Mitotic activity of micro-
glial  cells  can  additionally  be  elevated  by  colony
stimulating  factor-1  (CSF-1),  which  production  is
increased by  IL-1, TNFa ,
124 granulocyte-macrophage
Nitric oxide in glial cells
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FIG. 2. Microglial cells and astroglial cells in rat brain in vivoand in vitrostained for GSA-l-B4-isolectin and GFAP respectively.
(A) GFAP staining of astroglial cells in rat brain; (B) GSA-l-B4-isolectin staining ramified microglial cells in a rat brain; (C) GFAP
in vitroin a purified astroglial cell culture; (D) GSA-l-B4-isolectin in vitroin a purified ameboid microglial cell culture. A, B, bar
= 66mm; C,D, bar = 25mm.colony-stimulating factor (GM-CSF)
41,109,110,122,125–127
or microglial mitogen (MM).
111
The microglial cells undergo morphological chan-
ges in response to factors released by or through cell–
cell  contact  with  astrocytes. These  factors  derived
from astrocytes, induce microglial cells to become the
ramified,  functionally  resting  cells  in  vitro,  while
inflammatory mediators like interferon g (IFNg ) and
LPS induce microglial cells to become ameboid.
128,129
Also,  blood  monocytes  and  spleen  macrophages
differentiate into ramified microglial cells when cul-
tured  onto  an  astroglial  cell  monolayer.
130,131 This
illustrates the capacity of astroglial cells to transform
cells from monocytic origin into cells with microglial
cell morphology.
In  addition,  astroglial  cells  have  been  shown  to
functionally  regulate  microglial  cell  activity.  The
endotoxin induced synthesis of iNOS and release of
NO but not the production of IL-1b by microglial cells
is  inhibited  in  the  presence  of  astroglial  cells  in
vitro.
51
Apparently  both  glial  cells  communicate  through
the production of various factors including cytokines
and growth factors. In this way the glial cells appear
to tightly regulate  each others  morphology, activity
and secretion of products.
Glia–neurone interactions
The presence of glia-derived cytokines in the CNS and
the function of these cytokines in vitro suggest that
they are important for normal brain development and
homeostasis.
132,133 However, excessive expression of
these  cytokines  may  be  a  factor  in  abnormal  glial
functions leading to neuropathological events.
In general astrocytes have been  found  to express
neurotrophic  factors  such  as  ciliary  neurotrophic
factor  (CNTF),  neurotrophin-3,  fibroblast  growth
factor (FGF) and NGF near the site of injury.
134,135 In
vitro experiments show that astrocytes protect dopa-
minergic  neurons  against  H2O2 toxicity
136 through
actions of glutatione. Interestingly, survival  of these
dopaminergic neurones in vitro is enhanced by the
presence of glial cells derived from striatal astroglia:
the target-derived astroglial cells, illustrating astroglial
cell heterogeneity.
137,138The survival of dopaminergic
neurones  is  promoted  by  glial  cell-lined  derived
neurotrophic factor (GDNF) in vivo.
139 In vitro co-
cultures  of  neurones  and  astrocytes  induced  an
increased cell survival and neurite outgrowth
140–142
and  axons might  trigger  glial  differentiation.
143 The
ability of astrocytes to augment neuronal survival was
increased  after  treatment  of  the  astrocytes  with
macrophage  conditioned  medium
144 indicating  that
factors produced by macrophages induce the produc-
tion of neurotrophic factors.
Neurones are less sensitive to  oxygen  or glucose
deprivation  or  treatment  with  glutamate  when  co-
cultured  with  astrocytes.
145 In  addition  astrocytes
increase neuronal survival under pathological condi-
tions  since  they  have  an  energy  reserve  stored  as
glycogen  which  becomes  available  for  neurones
under  conditions  of energy  substrate  limitations.
146
Astroglial  cells  are  important  in  the  metabolism  of
glutamate and GABA and other neurotransmitters,
147
and maintain the microenvironment by regulating the
ionic composition of the extracellular space around
the neurones.
148
Neurotrophic  effects  i.e.  neuronal  survival  and
neurite extension have also been reported by micro-
glial  cell  conditioned  medium
149 and  more  specifi-
cally  by  the  production  of  NGF
150 and  thrombo-
spondin.
151,152 In addition secretion of IL-6, IL-1, FGF ,
TGFb , TNFa by  microglial  cells  and  astroglial  cells
may  stimulate  nerve  growth  factor  production  by
astroglial  cells  for  the  regeneration  of  neu-
rones.
93,134,153 –158 These factors also directly improve
the  survival  of  neurones  and/or  have  synergistic
effects with NGF .
159,160
While in general factors released by astroglial cells
actually increase the survival of neurones,
161 micro-
glial  cells  in  contrast,  can  directly  participate  in
neuronal cell death through the release of neurotox-
ins.
162 Microglial  cells  have  been  reported  in  the
presence of degenerating neurones in various regions
in the brain.
18,163 –165 In these regions the microglial
cells clearly contribute to the removal of pycnotic cell
bodies.  Prior  to  this  scavenger  role,  the  active
participation of microglial cells in neurite amputation
has been shown on electron microscopic pictures of
microglial  cells  engulfing  axon  processes  which
display  no  obvious  signs  of  degeneration.
166 It  is
therefore thought that interactions between neurones
and  microglial  cells  may  not  be  restricted  to  cell
debris scavenging but microglial cells may also induce
neuronal cell death.
In vitro studies have demonstrated the production
of  many  different  neurotoxins  by  microglial  cells.
Activated  microglial  cells  release  several  cytotoxic
compounds i.e. reactive oxygen intermediates,
167,168
NO,  proteases
51,169 –172 and  inflammatory  cytokines
i.e. IL-1, TNFg or TNFa ,
50,56,119,127,157,173,174 that play a
role in neuronal damage in the CNS. Finally microglial
cells produce large amounts of glutamate and aspartate
in vitro.
175The release of these excitatory amino acids
points to a further role of microglial cells in NMDA
receptor-mediated  neuronal  injury.
175 In  addition,
cultured microglial cell release large amounts of H2O2,
which  leads  to  neuronal  cell  death  in  neurone–
microglial cell cocultures.
172,176,177
Taken together, activated microglial cells display a
broad repertoire of cytotoxic functions which could
be involved in  tissue damage during CNS injury. In
addition, microglial cells activate astroglial cells in a
way that benefits regeneration. Further, the effect of
neurotoxic factors released by microglial cells can be
V. A. M. Vincent et al.
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cells.
178,179 This illustrates the fascinating and delicate
interactions  that  exist  between  glial  cells  and  neu-
rones, which are crucial in maintaining neural func-
tioning and integrity. These studies have contributed
towards a  concept which  considers reactive micro-
glial  cells  as  an  opposing  force  to  neurotrophic
astroglia,  the  two  glial  cell  populations  rivaling  in
regulating survival of neurones.
180
Nitric Oxide in the CNS
Various cell types in the CNS, i.e. neurones, endothe-
lial cells, microglial cells and astroglial cells produce
NO.  Different  isoforms of the  nitric oxide  synthase
(NOS) are responsible for the production of NO by
these cell types. NO in the brain is multipotent and is
responsible for blood flow regulation, may act as a
neurotransmitter or as a neurotoxic agent, depending
on the cellular source, amount and production site.
Isoforms of nitric oxide synthase
NO, a free radical gas, was found to be responsible
for  the vasodilatation  in  arteries and  at  first named
endothelium derived relaxing factor (EDRF).
181 Later
the  source  of  NO  was  elucidated  revealing  the
enzymatically conversion of L-arginine to L-citrulline
by NO synthase whereby NO is produced (Fig. 3).
182
Three  isoforms  of  NOS,  encoded  by  different
genes
183 have  been  characterized,  isolated  and
cloned  to  further  study  the  physiologic  and/or
pathologic  functions  of  NO.
184 All  three  isoforms,
endothelial  (eNOS,  ecNOS  or  type  III),  constitutive
(cNOS,  nNOS,  bNOS  or  type  1)  found  in  astroglial
cells  and  neurones  and  inducible  (iNOS,  mNOS,
macNOS or type II), NOS are found in the CNS and
play  a  role  in  certain  physiological  or  pathological
functions  of  the  CNS  (see  following  section).
185
Constitutive NOS is constitutively expressed in neu-
rones,  is  Ca
2+ and  calmodulin  dependent,  and
mediates  the  production  of  only  small  amounts  of
NO after stimulation. This neuron derived NO is very
rapidly  produced  and  released  since  cNOS  is  con-
stitutively  expressed  and  does  not  require  mRNA
synthesis, acts as a neurotransmitter with properties
that differ from other neurotransmitters: (a) it is not
stored in vesicles, (b) there are no specific release or
uptake  mechanisms  and  (c)  its  transmission  is  not
synaptic. NO diffuses into the target cell and directly
regulates  enzymes  systems,  such  as  activation  of
guanylate  cyclase,  resulting  in  increased  cGMP  lev-
els.
186,187 NO  has  a  half  life  of  a  few  seconds  in
contrast to the milliseconds of the neurotransmitters
in classical synapses.
188,189 It is important  in neuro-
transmission,  and  NO  is considered a  candidate  for
a memory-related process named long-term-potentia-
tion  (LTP).
190,191 Indeed,  inhibitors  of  NOS  can
block LTP.
192,193 In areas such as the cerebral cortex,
hippocampus,  cerebellum  and  corpus  striatum,
cNOS  expressing  neurones  compose  1–2%  of  all
neuronal  cells.
194 Activation  of  cNOS  in  astroglial
cells  was  observed  after  challenge  with  calcium
ionophores, bradykinin  or glutamate.
185
Endothelial NOS (eNOS) produced by endothelial
cells is a constitutive Ca
2+-dependent enzyme that is
essential  for the control of vascular tone. NO trans-
duces a signal from the endothelial cell to the vascular
smooth muscle eventually  leading to  cGMP  produc-
tion and vasodilation. In the brain, eNOS-derived NO
regulates cerebrovascular blood flow.
195
Inducible  NOS  (iNOS)  is  a  Ca
2+ and  calmodulin
independent enzyme. It requires gene transcription,
is  slowly  produced  and  is  activated  only  under
pathological  situations  where  microglial  cells  and
macrophages exert  cytotoxic effects in  response to
cytokines.
196 The generation of NO by iNOS is long-
lasting, in contrast to the cNOS and eNOS isoforms
where  NO  is  generated  in  short  bursts.
197,198 The
mechanism of iNOS induction involves transcription
of  mRNA  and  novel  protein  synthesis  and  it  takes
several  hours  before  NO  is  generated  after  the
initiating signal.
199 It induces a 100-fold higher local
concentrations of NO than eNOS or cNOS and act as
a  antimicrobial  defence  mechanism  of  the  immune
system. iNOS is not expressed in normal brains but
expression can be induced in astroglial and microglial
cells  through  viral  infection  or  trauma.
200,201 It  is
mainly expressed under inflammatory conditions, and
after transient ischaemic periods.
202 –205
Nitric oxide in neuropathology
NO can be neurotoxic under different circumstances.
The NO mediated neuronal cell death can be induced
by overexpression of cNOS in neurones and astroglial
cells or iNOS induction in glial cells, both pathways
will be further discussed below (see Fig. 4).
cNOS induced NO mediated neurotoxicity
Glutamate binding to its NMDA receptor induces NO
production  by  cNOS  activation.  Derangements  of
Nitric oxide in glial cells
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FIG. 3. Biosynthesis of NO through the so-called L-arginine-
NO pathway, adapted from Ref. 372.O2
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glutamate  neurotransmission  leading  to  neurotox-
icity  has  been  implicated  in  Alzheimer’s  disease,
Huntington’s  disease,  amyotrophic  lateral  sclerosis
(ALS), epilepsy and stroke.
206,207 Glumate neurotox-
icity  is  demonstrated  to  be  mediated  through  NO
production.  After  binding  of  glutamate  with  the
NMDA  subtype  of glutamate  receptors,  Ca
2+ enters
the channel and binds to calmodulin, a cofactor for
cNOS  and  stimulates  NOS  activity  whereby  NO  is
produced.
208 In  addition,  O
–
2 is  produced  which
results  in  the  formation  of  ONOO
- which  subse-
quently  leads  to  neuronal  death.
209–211 Neurones
obtained from cNOS null transgenic mice are mark-
edly  resistant  to  ischaemic  conditions,
212 in  which
the  primary  mechanism  of  damage  is  mediated  by
activation  of  the  NMDA  receptor  and  subsequent
formation of NO. This indicates that cNOS is capable
of  producing  neurotoxic  amounts of  NO.
213
iNOS induced NO mediated neurotoxicity
The iNOS-mediated release of NO by astrocytes and
microglial  cells  in  the  brain  may  be  important  in
antimicrobial  or tumoricidal  responses to  inflamma-
tory signals.
197 In acute CNS inflammatory conditions
like rabies, herpes simplex, Borna, and lymphocytic
choriomeningitis  virus,  iNOS  is  expressed
200,214–217
as well as in experimental pneumococcal meningitis
and toxoplasmosis and in humans during encephali-
tis.
130,218–220 iNOS  mediated  NO  is  considered  to
mediate neuronal and oligodendrocyte degeneration
under  neuropathological  conditions.
202,221,222 The
role of iNOS in neuropathology in general is indirect,
microglial  cells  and/or  macrophages  become  acti-
vated  either  through  direct  infection  with  virus  or
other pathogens, or by local cytokine production and
subsequently produce iNOS which eventually leads to
damage. Excessive amounts of NO produced by glial
cell are probably neurotoxic. iNOS-derived NO is one
of the major sources of toxic free radicals in the brain,
since  its  reaction  with  the  superoxide  anion  (O
–
2)
leads  to  the  formation  of  peroxynitrite  anion
(ONOO
–)  which  is  an  extremely  potent  oxidizing
agent.
223 Peroxynitrite  generates  DNA-single-strand
breaks with subsequent activation of the DNA repair
enzyme  poly ADP  ribosyltransferase  (PARS).
224 Fur-
thermore, NO and peroxynitrite have been shown to
inhibit  the mitochondrial  respiratory  chain  and  dis-
rupt normal cellular iron homeostasis.
201,225–227 Per-
oxynitrite  and/or  NO  can  terminally  damage  neu-
rones, leading to cell death.
228 –232 Low levels of or
sustained  exposure  to  NO  or  peroxynitrite  cause
apoptosis, whereas sudden exposure to high concen-
trations of NO or peroxynitrite leads to necrosis.
233
NO in Alzheimer’s disease and MS
iNOS expression is found in Alzheimer’s disease
234,235
and  in  experimentally  infected  brains  of  rats  with
various  viral  agents.
200 NO  has  been  implicated  in
demyelination  and  destruction  of  oligodendrocytes
and subsequent demyelination, the process found in
MS
236 and  in  the  primary  animal  model  for  MS,
experimental allergic encephalomyelitis (EAE).
216,237
During  EAE,  iNOS  mRNA  is  detectable  before  the
onset  of  the  clinical  symptoms  and  the  levels  of
protein correlate with the severity of the disease.
200
Further evidence supporting a  role for iNOS in the
pathogenesis of MS is the finding that human iNOS
protein and mRNA is markedly elevated in the active
lesions in brains of MS patients.
238,239 In MS lesions,
macrophages  appear  to  produce  iNOS  and  are
NADPH-diaphorase positive after histochemical stain-
ing.
240 In another study, NADPH-diaphorase activity in
MS  lesions  was  found  in  reactive  astroglial  cells
239
which was later shown to be cNOS.
240 The cellular
source of iNOS mRNA expression in brains of patients
with  MS  has  been  confirmed  to  be  macrophages/
microglial cells.
238 In EAE an increase was found in
eNOS  in  blood  vessels  in  the  inflamed  lesions  and
increase  in  iNOS  in  infiltrating  inflammatory
cells.
216,241 iNOS expression can be (further) induced
by  cytokines  like TNFa ,  IFNg and  IL-1,  that  are  all
detected in brains of MS patients.
242 –245
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FIG.  4.  NO  as  neurotoxin.  Excessive  NO  is  formed  on
sustained  glutamate  stimulation  of  NMDA  receptors  by
cNOS in neurones or by activation of iNOS or cNOS in glial
cells. NO freely diffuses to adjacent target neurones where it
combines with the O2
– to yield the peroxynitrite, ONOO–,
which  is  an  extremely  potent  oxidant.  Although  NO  can
function as a toxin directly, the peroxynitrite pathway may be
the major pathway of cell death, adapted from Ref. 303.
NO in AIDS dementia complex
iNOS-mediated NO production has also been descri-
bed  to  be  involved  in  acquired  immune  deficiency
syndrome  (AIDS)-related  neuropathology.  iNOS  pro-
tein and mRNA was found in the CNS of patients with
AIDS  dementia  complex  (ADC),
246,247 and  isexpressed  at  higher  levels  than  in  brains  of  AIDS
patients  without  neurological  symptoms.  The  cell
types expressing iNOS however, remain unknown. In
these patients there is a clear correlation between the
severity of the dementia and iNOS expression in the
brain. In addition in brain tissue of simian immunode-
ficiency  virus  (SIV)  infected  monkeys  iNOS  mRNA
was  detected.
248 The  microglial  cells  have  been
postulated to be involved in the pathogenesis of ADC
because  they  are  preferentially  infected  by  the
virus.
43,249 –251 Neuropathological  manifestations
such as loss of cortical neurones, loss of synapses and
neuronal apoptosis have therefore been suggested to
be mediated indirectly by cytokines like TNFa
252,253
and  IL-1
254–256 or  by nitric oxide.
257–261 TNFa , IL-1
and iNOS have been demonstrated in brains of AIDS
patients
247,256,262 –265 as  well  as  in  ADC
patients
259,266,267 (Vincent et al., submitted). In cyto-
megalovirus  (CMV)  infected  retinas  from  AIDS
patients iNOS immunoreactivity and NADPH-diaphor-
ase were found in (CMV)-infected cells identified as
M¨ uller cells and astrocytes.
268
NO in parkinson’s disease
In  Parkinson’s  disease,  which  is  primarily  charac-
terized by a loss of midbrain dopaminergic neurones,
iNOS was present in glial cells
269 in the mesecephalon
probably  in  activated  macrophages.
269 In  addition,
NOS inhibitors attenuate malonate-induced degenera-
tion by NMDA receptor activation of the nigrostriatal
pathway  in  rats
270 suggesting  a  role  for  NO  in
neurodegeneration. The inhibition of tyrosine hydrox-
ylase  resulting  in  reduced  dopamine  synthesis  is
triggered  by  peroxynitrite,  a  reaction  product  of
NO.
NO in brain activation
During ischaemic brain  damage eNOS is induced in
endothelial cells which then has beneficial effects by
enhancing the vasodilation, further increasing blood
flow in the peri-infarct area.
272,273 In addition iNOS is
induced  leading  to  NO  production,  which  leads  to
neuronal  death  after  cerebral  ischaemia.
274 During
postnatal brain development of rats, large numbers of
NADPH-diaphorase  positive  neurones  and  NADPH-
diaphorase positive cells with macrophage morphol-
ogy were observed. The latter are possibly involved in
developmental shaping of the brain, which includes
cell death and fagocytosis of cellular debris.
275 High
levels  of  NADPH-diaphorase  were  found  in  evenly
distributed  astroglial  cells  in  areas  surrounding  a
mechanical lesion in the brain. Within the lesion the
NADPH-diaphorase positive cells most probably were
macrophages.
276
Thus, although iNOS and NADPH-diaphorase activ-
ity can be induced in astrocytes and microglial cells
through viral infection or trauma most of the studies
have  revealed  iNOS  immunoreactivity  and  iNOS
mRNA  in  the  brain  in  infiltrating  macrophages  or
microglial cells.
210 In general, exposure of brain cells
to signals, such as microbial products, viruses, gluta-
mate  or  yet  unknown  signals  in  diseases  like  MS,
Alzheimer’s  and  Parkinson’s  disease  leads  to  the
secretion  of  inflammatory  cytokines  that  induce
either  de  novo synthesis  of  iNOS  by  glial  cells  or
cNOS  in  astroglial  cells  or  neurons  as  has  been
demonstrated  in  in  vitro studies. This  NO  may  be
neurotoxic  and  may  subsequently  lead  to
neuropathology.
Production of iNOS in vitro
To answer some more fundamental questions regard-
ing iNOS production and regulation in vitro studies
are widely used. Sources, induction mechanism and
intervention of iNOS production are studied in detail
in various glial cell cultures. In addition, a model has
been  developed  that  allows  studies  of  the  possible
neurotoxic effects of glial NO, on cultured neurons.
These in vitro studies have led to new insights in the
functions  of  glial  cells  in  normal  brain  and  in
neuropathology.
Several  techniques have been  described for isola-
tion  of  rat  murine  or  human  brain  microglial  cells,
astroglial  cells  and  maintenance  of  these  cells  in
vitro.
118,240,277–282 The microglial cells and astroglial
cells are isolated from mixed  glial  cultures in  most
instances  or  from  disrupted  adult  or  neonatal  tis-
sue.
53,127,171,279,283–285 In tissue culture, the ameboid
and  ramified  microglial  cell  can  be identified, most
probably corresponding to its morphological diversity
in the adult brain.
286The astroglial cell cultures can be
contaminated with microglial cells, since the purifica-
tion of astroglial  cells is a  rather delicate technique
and  microglial  cells  remain  a  significant  contami-
nant.
56,161,287 Many  studies  showing  production  of,
for example, cytokines like IL-1 or TNFa by astroglial
cells  in  vitro have  to  be  interpreted  with  care.  In
vitro studies also provide a very useful technique to
study both the functions of glial cells and of neurones
as well as the interactions between these cell types.
Therefore techniques for selective isolation, co-cultur-
ing, labeling and  stimulation  of microglial  cells and
astroglial  cells  allow  investigators  to  study  some
fundamental questions in neuro-immunology.
Glial cell-derived iNOS
iNOS expression by glial cells has been studied in in
vitro systems  of  highly  purified  microglial  cell  and
astroglial cell cultures and in mixed cultures contain-
ing  both  cell  types  from  human  or  rodent  brain.
Following  incubations  with  various  stimuli,  both
microglial and astroglial cells have been demonstrated
to produce nitrate, one of the end-products of nitric
oxide oxidation.
203
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microglial  cells  in  response  to  IL-1b ,  LPS  or  Gram-
positive bacterial products.
185,259,288,289 IFNg induces
NO in  microglial  cells  and  macrophages but  not  in
astroglial cells,
203,221,290–292 while synergism of IFNg
and IL-1b or TNFa induce significant levels of nitrite
in rodent and human astroglial cells.
203,239,250,293,294
LPS induction of iNOS required CD14 expression on
glial cells.
295 As yet it is not clear whether cytokines
activate  gene  expression  via  one  or  multiple  path-
ways. Experiments with phorbol esters, which induce
iNOS, suggest that protein kinase C may be involved
in  the  induction  process  in  microglial  cells  and
astrocytes.
296
Agents  like  IFNg and  LPS  are  more  effective
inducers of iNOS in rodent than in human microglial
cells,
198,250,288,297 which  therefore  appears  to  be
species-dependent as described for NO production by
retinal  pigment  epithelial  cells.
298 Recently,  some
studies  did  however  reveal  NO  and  iNOS  mRNA
production in human ramified microglial cells upon
LPS or TNFa stimulation.
267,299
HIV or the HIV type I coat proteins gp120 or gp41
induce iNOS in cultured microglial cells, monocytes
or  macrophages.
9,246,257,258,266 In  human  fetal  glial
cells, comparable amounts of NO were induced by
gp120, gp41 and the proinflammatory cytokines IFNg
and  IL-1b .
9 HIV-infected  brain  mononuclear  macro-
phage secrete NO and O
–
2,
266 especially after immune
activation and TNFa further increases NO production.
In  MS  and  EAE,  macrophages  isolated  from  lesion
areas  produced  significant  amounts  of  nitrite  and
were shown to be iNOS positive without any further
stimulation.
240,300
b -amyloid,  the  major  component  of  the  senile
plaques  in Alzheimer’s  disease,  causes  a  significant
increase in NO by microglial cells and not in astroglial
cells. The NO production induced by the b -amyloid
was  increased  by  IFNg
301,302 or  phorbol-myristate-
acetate (PMA) challenge.
168
Studies that have attempted to compare rat micro-
glial  cell  and  astrocyte  NO  production  have  con-
cluded that microglial  cells produce more NO on  a
per cell basis than astrocytes.
202,222,290 This has led to
the  suggestion  that  activated  microglial  cells  rather
than  astrocytes  are  the  principal source  of  reactive
nitrogen intermediates in the CNS, and that the NO
produced  by  astroglial  cells  might  be  beneficial,
whereas microglial-derived NO might be involved in
neurotoxicity.
185
Nitric oxide mediated neurotoxicity in vitro
In vitro co-cultures of glial cells with neurones have
proven to be a valuable tool in the identification  of
NO as a neurotoxin and the cellular sources of NO.
Exogenous NO generated from NO donors have been
shown to kill neurones in vitro.
224 Cytokine-activated
murine microglial cells and astroglial cells apparently
generate substantial amounts of NO that kill neurones
in vitro,
202,222,259,288,303,304 since inhibition of endo-
genously  formed  NO  by  specific  NOS  inhibitors
blocks this microglia- or astrocyte-mediated neurotox-
icity.
202,260,305 For example, factors like LPS, gp41 and
b -amyloid  can  indirectly  kill  neurones  in  mixed
cultures with glial cells, which is abrogated by NOS-
inhibitors.
246,301 LPS or cytokine activated glial cells
stimulate  the  production  of  neurotoxins,  e.g.  NO,
because LPS and cytokines do not directly influence
the  viability  of  purified  neurones.
307 These  studies
clearly  illustrate  the  indirect  mechanism  by  which
neurones are thought to be killed.
306
The  glial  cells  produce  large  amounts  of  NO  by
iNOS activity which can form peroxynitrite which is
toxic  to  neurones  as  previously  described.  In  addi-
tion, glutamate neurotoxicity is also mediated by NO
in  primary  neuronal  cultures.
303 Peroxynitrite,  NO
and NMDA can damage neurones in vitro leading to
necrotic  or  apoptotic  cell  death  pending  on  the
concentration  and  duration  of  the  exposure.
229 In
addition, oligodendrocytes are also being killed by an
NO  dependent  mechanism  by  ameboid  microglial
cells  in  vitro,  suggesting  that  iNOS  expression  by
invading and intrinsic brain cells play a role in lesion
formation in multiple sclerosis.
221
Although  glial  cells  produce  various  neurotoxins
i.e.  TNFa ,  glutamate  and  PAF ,  production  of  NO
appears  to  play  a  key  role  in  different  neurotoxic
pathways  since  inhibition  of  iNOS  spares  the  neu-
rones.
260,305,308 These  in  vitro findings  suggest  an
important  role  for  glial  iNOS  derived  NO  in  the
pathophysiology of CNS diseases.
Regulation of NO Production
Since  NO  is  shown  to  play  an  important  role  in
neurotoxicity,  inhibition  of NO could be a  possible
route  of  intervention  in  the  prevention  of  neu-
ropathogenesis. Experimentally often used inhibitors
of NOS production are synthetic arginine analogues
like  N
G-mono-methylarginine  (NMMA),  Nw-nitro-
L-arginine  methyl  ester  (L-NAME),  aminoguanidine
and N
G-nitroarginine.
239,258,309 They are often used in
in  vitro studies to  certify  the  L-arginine dependent
origin of NO.
Intervention of NO synthesis in vivo by using NOS
specific inhibitors has been described in EAE using
different  arginine  analogues  e.g.  aminoguanidine,
L-NMMA  and  L-NAME.
241,300,310,311 In  these  experi-
ments, the effects of these inhibitors on the clinical
score of EAE were not conclusive. The aspecificity of
these inhibitors for the subtypes of NOS, and thereby
effects  on  eNOS  and  cNOS  leading  to  e.g.  vascular
changes,  may  explain  these  different  results.  The
search  for  pharmacological  tools  that  selectively
inhibit iNOS, eNOS or cNOS is currently getting much
attention and thus far has yielded some agents. The
V. A. M. Vincent et al.
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N
G-nitro-L-arginine shows a preference for eNOS and
cNOS over iNOS, whereas L-N
6-(1-iminoethyl)lysine is
selective for iNOS over cNOS.
312
Interestingly, NO can also act as a negative feedback
signal  on  iNOS  activity,  by  inhibiting  the  transcrip-
tional  induction  of NOS, indicating a self-regulatory
mechanism.
313,314 In  cultures  of  rat  astroglial  cells
norepinephrine  and  dexamethasone  have  been
shown  to  suppress  iNOS  induction.
257,288,289,315 In
addition, prostanoids are involved in the regulation of
iNOS since prostaglandin E2 but also cyclooxygenase
inhibitors suppress iNOS expression in LPS activated
rat  microglial  cells.
316 In  addition  several  endoge-
nously  produced  cytokines  have  been  shown  to
inhibit  NO  production.  TGFb ,  IL-4  and  IL-10,  are
known  to  inhibit  NOS  activity  in  mono-
cytes
9,221,266,305,317–320 and  synergistically  suppress
NO production.
70 TGFb is an important modulator in
the brain during development
321 and TGFb has been
demonstrated in brains of HIV patients, around brain
tumours, in MS, Alzheimer’s disease, brain ischaemia,
peripheral  nerve transections and  in  several  experi-
mental lesions in animals.
322–330
Transforming growth factor b (TGFb )
TGFb is a 25kDa homodimeric protein secreted by a
variety of cells as a latent protein complex.
60 There
are at least five distinct gene products that constitute
the TGFb family, TGFb 1 through TGFb 5 which show a
high  degree  (70–80%)  of  amino  acid  sequence
identity.  The  three  highly  homologous  mammalian
TGFb isoforms  are TGFb 1, TGFb 2  and TGFb 3  with
relatively high sequence similarities but differences in
receptor  binding  affinities.
331 Three  different TGFb
receptors  have  been  identified,  type  I  to  type  III,
which  distributions  are  ubiquitous  in  various  body
tissues.
In  a  variety  of studies  of microglial  cell  cultures,
TGFb has  been  shown  to be a  potent  immunosup-
pressive cytokine
332 and inhibits NO production by
microglial cells.
333 TGFb inhibits iNOS expression by
decreasing  iNOS  mRNA  stability  and  inhibiting  its
translation  and  increasing  iNOS  protein  degrada-
tion,
334 resulting  in  reduced  NO  production.
317,335
Not only NO but also O
–
2 is inhibited by TGFb
71 and
thereby the formation of the highly toxic peroxyni-
trite is prevented.
TGFb is  a  chemotactic  agent  for  monocytes  and
macrophages and is suggested to be important in the
recruitment of circulating monocytes into brain tissue
after  damage.
336 TGFb has  protective  effects  in
different  experimental  autoimmune  diseases
337–339
whereas  neutralizing  antibodies  to  TGFb 1  worsen
clinical severity.
340,341 During EAE, and after cerebral
trauma  or hypoxic-ischaemic damage, TGFb expres-
sion  is  increased  when  neurological  symptoms  are
severe, which might indicate an inflammation limiting
of TGFb in  the  recovery  phase  thereby  controlling
the inflammatory reaction.
342–345
Astroglial  and  microglial  cells  are  known  to  con-
stitutively  produce  TGFb in  vivo
61,324,325 and  in
vitro.
62,103–105,346,347The isoforms TGFb 1, TGFb 2 and
TGFb 3 are produced by astroglial cells in vitro, while
microglial  cells  only  produce  the TGFb 1  isoform.
60
TGFb production in microglial and astroglial cells is
increased after TNFa
348 or IL-1
104,349 or TGFb expo-
sure itself.
350
In co-cultures of astroglial cells and microglial cells
bioactive TGFb was found to inhibit iNOS expression
and  thereby NO production by endotoxin activated
microglial cells. The presence of astroglial cells was
shown to be essential  for the activation  of TGFb in
these  co-cultures  of  astroglial  and  microglial  cells
62
(see Fig. 5).
Regulation of TGFb activity
TGFb is produced by glial cells in a latent, inactive
form
60 and  forms  a  complex  with  the  latency-
associated  protein  (LAP).
351,352 Activation  of  latent
TGFb consists of releasing TGFb from the LAP, which
occurs after heat treatment, acidification, alkalization
or proteolysis by plasmin.
351,353 Plasmin is generated
by  the  plasminogen  activator  system.  Plasminogen
activators (PA)s are serine proteases consisting of a
50 kD  urokinase-type  plasminogen  activator  (u-PA)
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FIG. 5. Effect of immunoneutralizing of TGFb 1 and TGFb 2 on
endotoxin  induced expression  of IL-1b and iNOS by con-
fluent mixed glial cell cultures containing mainly astroglial
cells and microglial cells. Numbers of immunopositive cells
in  24h  endotoxin  (1m g/ml)  stimulated  mixed  glial  cell
cultures. Different cultures were stained with the microglial
cell marker GSA-l-B4-isolectin (LECT) or for IL-1b or iNOS.
Data  are  expressed  as  the  mean  and  SE  (n =  3).  **P <
0.005.LAP
TGFb TGFb
Plasminogen Plasmin
tPA
uPA
PAI
`Latent’ TGFb `Active’ TGFb
and a 68 kD tissue-type plasminogen activator (tPA),
secreted as inactive pro-forms, which major substrate
is plasminogen. uPA and tPA can cleave plasminogen
into  plasmin  which  subsequently  activates  latent
TGFb
354,355 (Fig. 6). These PAs are specifically inhib-
ited  by  the  plasminogen  activator  inhibitors  (PAI),
PAI-1, PAI-2 and PAI-3 (Table 1),
356,357 by formation of
a tight complex with PAs.
Plasmin has a broad  range of substrates including
fibrin, fibronectin, laminin and matrix metalloprotei-
nases (MMP). The PAs and PAIs play an important role
by fine regulating the proteolytic degradation of fibrin
clots  (fibrinolysis)  in  the  circulation,  mediated  by
plasmin
354,358 and therefore tPA is now used for the
treatment  of thrombotic stroke. Only recently func-
tions for PA were found in the brain, and proteolysis
of the extracellular matrix (ECM) by MMP activation,
amplified by PAs, has been suggested. The breakdown
of  the  ECM  is  thought  to  be  involved  in  brain
development  and  neurite  outgrowth  but  also  in
neuropathology  like  growth  and  invasion  of  brain
tumours, leukocyte infiltration in MS and EAE, break-
down of the BBB and nerve demyelination.
311
Microglial cells secrete proteases such as elastase,
uPA  and  secrete  plasminogen
359,360 which  have  a
direct  neurotrophic  effects  on  various  types  of
neurones.
361 Astroglial  cells  can  synthesize  and
secrete both tPA and uPA as well as PAI-1,
178,362–364
and  tPA  is  involved  in  motor  learning  but  also  in
Alzheimer’s  disease  and  neuronal  degenera-
tion.
365–367 PAs and PAIs have been demonstrated in
cerebrospinal  fluid  of  patients  with  neurological
disease
368,369 and tPA expression was found
370 in MS
lesions supporting a role of PA and PAI in neuropatho-
logical processes.
An important role of tPA and PAI and the regulation
of TGFb activity was shown in a glial cell coculture.
178
tPA and PAI-1 produced by astroglial cells regulated
the  bioactivity  of TGFb ,  and  thereby  indirectly  the
production  of  NO  by  microglial  cells.
178 Therefore,
we  postulate  that  tPA-mediated  activation  of TGFb
plays an important role in neuroprotection.
Summary
In neuropathological conditions such as Alzheimer’s
disease, Parkinson’s disease, AIDS dementia complex
and  multiple  sclerosis,  activation  of  microglial  cells
and  astroglial  cells  is  evident.  Under  these  neu-
ropathological conditions cellular damage in the brain
is  considered  to  arise  indirectly  from  cytotoxic
substances produced by activated glial cells. One of
these toxins is NO which has been demonstrated to
be produced during several neuropathological condi-
tions. High NO levels are produced by glial cells and
exert  neurotoxic  effects. Astroglial  cells  and  micro-
glial cells communicate in various ways to reduce NO
production  by  microglial  cells which is essential  to
maintain homeostasis in the brain. The production of
TGFb by  glial  cells  and  its  activation  by  astrocyte-
derived  tPA  represents  one  mechanism  by  which
astroglia limit NO production in the brain.
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